Abstract
Eighty-three patients with malignant lymphoma of intermediate and high histologic subtypes were randomly assigned to receive induction chemotherapy with either of two intensive regimens: CHOP-Bleo (cyclophosphamide, adriamycin, vincristine, prednisone and bleomycin) or m-BACOD (low-dose methotrexate, bleomycin adriamycin, cyclophosphamide, vincristine and dexamethasone). The median follow-up study is 5 years. The two therapies were not significantly different in regard to response rates (52 to 59%), duration of complete remission (27 months vs 24 months) and survival, but m-BACOD was significantly more toxic than CHOP-Bleo. The relative small proportion of long-term disease free-survivors with both regimens underscores the need for other therapeutic approaches.
Publication types
-
Clinical Trial
-
Comparative Study
-
English Abstract
-
Randomized Controlled Trial
MeSH terms
-
Actuarial Analysis
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Cyclophosphamide / administration & dosage
-
Dexamethasone / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Humans
-
Leucovorin / administration & dosage
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, Non-Hodgkin / mortality
-
Lymphoma, Non-Hodgkin / pathology
-
Male
-
Methotrexate / administration & dosage
-
Mexico / epidemiology
-
Prednisone / administration & dosage
-
Prospective Studies
-
Risk Factors
-
Survival Rate
-
Vincristine / administration & dosage
Substances
-
Bleomycin
-
Vincristine
-
Dexamethasone
-
Doxorubicin
-
Cyclophosphamide
-
Leucovorin
-
Prednisone
-
Methotrexate
Supplementary concepts
-
CHOP-B protocol
-
M-BACOD protocol